12.2.Dabrafenib–trametinib indications published in EMA Data Sheet not funded by SNS in Spain:EMA #1 indication: Dabrafenib in combination with trametinib is indicated for treatment of adult patient with advanced NSCLC with BRAF V600 mutation [77, 78].Clinical evidence approval EMA indication #1: The efficacy and safety were studied in a phase II, BRF113928, three-cohort study, multicenter, non-randomized and open-label study. This evidence concerns the gene BRAF and non-small cell lung carcinoma.